The use of intramuscular benzodiazepines and antipsychotic agents in the treatment of acute agitation or violence in the emergency department

Journal of Emergency Medicine

Volumn 31, Issue 3, 2006, Pages 317-324

  Rund, Douglas A ^a   Ewing, John D ^b   Mitzel, Katherine ^a   Votolato, Nicholas ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

acute agitation in the emergency department; antipsychotic agents; benzodiazepines; injectable atypical antipsychotic medications; psychiatry; psychosis

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHLORPROMAZINE; DIPHENHYDRAMINE; DROPERIDOL; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; LORAZEPAM; MIDAZOLAM; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

AGITATION; ALGORITHM; ANTICHOLINERGIC EFFECT; ARTICLE; BIPOLAR DISORDER; BODY WEIGHT; DEATH; DELIRIUM; DEMENTIA; DIABETES MELLITUS; DIZZINESS; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DYSTONIA; EMERGENCY TREATMENT; EMERGENCY WARD; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INJECTION SITE PAIN; MENTAL DISEASE; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QT PROLONGATION; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; TORSADE DES POINTES; VIOLENCE; WEIGHT GAIN;

ALGORITHMS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG THERAPY, COMBINATION; EMERGENCY SERVICE, HOSPITAL; EMERGENCY TREATMENT; HUMANS; PSYCHOMOTOR AGITATION; VIOLENCE;

EID: 33748557203     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2005.09.021     Document Type: Article

References (52)

1. Allen M.H. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry 61 Suppl 4 (2000) 11-20
2. Allen M.H., Currier G.W., Hughes G.W., et al. The Expert Consensus Guideline Series: treatment of behavioral emergencies. Postgrad Med (2001) 1-88 (Spec No)
3. Williams E.R., and Shepherd S.M. Medical clearance of psychiatric patients. Emerg Med Clin North Am 18 (2000) 185-198
4. Mayo-Smith M.F. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med 164 (2004) 1405-1412
5. Currier G.W., and Simpson G.M. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 62 (2001) 153-157
6. Citrome L. Atypical antipsychotics for acute agitation. Postgrad Med 112 (2002) 85-88 94-6
7. Bellnier T.J. Continuum of care: stabilizing the acutely agitated patient. Am J Health Syst Pharm 59 Suppl 5 (2002) S12-S18
8. Battaglia J., Lindborg S.R., Alaka K., et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 21 (2003) 192-198
9. Salzman C., Solomon D., Miyawaki E., et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 52 (1991) 177-180
10. Dietch J.T., and Jennings R.K. Aggressive dyscontrol in patients treated with benzodiazepines. J Clin Psychiatry 49 (1988) 184-188
11. Wyant M., Diamond B., O'Neal E., et al. The use of midazolam in acutely agitated psychiatric patients. Psychopharmacol Bull 26 (1990) 126-129
12. Nobay F., Simon B.C., and Levitt M.A. A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. Acad Emerg Med 11 (2004) 744-749
13. Battaglia J., Moss S., Rush J., et al. Haloperidol, lorazepam or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 15 (1997) 335-340
14. Baldessarini R.J., Cohen B.M., and Teicher M.H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45 (1988) 79-91
15. th edn. (2003), McGraw-Hill, Columbus, OH 1816-1822
16. Zareba W., and Lin D.A. Antipsychotic drugs and QT interval prolongation. Psychiatr Q 74 (2003) 291-306
17. Resnick M., and Burton B.T. Droperidol vs. haloperidol in the initial management of acutely agitated patients. J Clin Psychiatry 45 (1984) 298-299
18. Thomas H.T., Schwartz E., and Petrilli R. Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Ann Emerg Med 21 (1992) 407-413
19. Richards J.R., Derlet R.W., and Duncan D.R. Chemical restraint for the agitated patient in the emergency department: Lorazepam versus droperidol. J Emerg Med 16 (1998) 567-573
20. Keenan S., Orellana F., and Barrueto Jr. F. Comment on article: the use and safety of droperidol in a high-risk, inner-city emergency department population. Acad Emerg Med 10 (2003) 908 author reply 908-9
21. Chase P.B., and Biros M.H. A retrospective review of the use and safety of droperidol in a large, high-risk, inner-city emergency department patient population. Acad Emerg Med 9 (2002) 1402-1410
22. Horowitz B.Z., Bizovi K., and Moreno R. Droperidol-behind the black box warning. Acad Emerg Med 9 (2002) 615
23. Kao L.W., Kirk M.A., Evers S.J., and Rosenfeld S.H. Droperidol, QT prolongation, and sudden death: what is the evidence?. Ann Emerg Med 41 (2003) 546-558
24. Hellewell J.S. Patients' subjective experiences of antipsychotics: clinical relevance. CNS Drugs 16 (2002) 457-471
25. Olfson M., Mechanic D., Hansell S., et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 51 (2000) 216-222
26. Gunasekara N.S., Spencer C.M., and Keating G.M. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs 62 (2002) 1217-1251
27. Daniel D.G., Zimbroff D.L., Potkin S.G., et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 20 (1999) 491-505
28. Keck P., Buffenstein A., Ferguson J., et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140 (1998) 173-184
29. Seeger T.F., Seymour P.A., Schmidt A.W., et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275 (1995) 101-113
30. Daniel D.G., Potkin S.G., Reeves K.R., et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind randomized trial. Psychopharmocology 155 (2001) 128-134
31. Geodon Package Insert. New York, NY: Pfizer; July 2002.
32. Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 17 (2003) 423-430
33. Glassman A.H., and Bigger J.T. Antipsychotic drugs: prolongated QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 158 (2001) 1774-1782
34. Biswas A.K., Zabrocki L.A., Mayes K.L., et al. Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. J Toxicol Clin Toxicol 41; (2003) 101-104
35. Trenton A.J., Currier G.W., and Zwemer F.L. Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs 17 (2003) 307-324
36. Viskin S. Long QT syndromes and torsade de pointes. Lancet 354 (1999) 1625-1633
37. Brook S., Lucey J.V., Gunn K.P., et al. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry 61 (2000) 933-941
38. Ananth J., Venkatesh R., Burgoyne K., Godasalli R., Binford R., and Gunatilake S. Atypical antipsychotic induced weight gain: pathopysiology and management. Ann Clin Psychiatry 16 (2004) 75-85
39. Liebzeit K.A., Markowitz J.S., and Caley C.F. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 11 (2001) 25-32
40. Ewing J., Rund D., and Votolato N. Evaluating the reconstitution of intramuscular ziprasidone (Geodon) into solution. Ann Emerg Med 43 (2004) 419-420
41. Moore N.A., Calligaro D.O., Wong D.T., et al. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Investig Drugs 2 (1993) 281-293
42. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 60 Suppl 10 (1999) 5-14
43. Koller E.A., and Doraiswamy P.M. Olanzapine associated diabetes mellitus. Pharmacotherapy 22 (2002) 841-852
44. Taylor D.M., and McAskill R. Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatr Scand 101 (2000) 416-432
45. Tollefson G.D., Beasley C.M., Tran P.V., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154 (1997) 457-465
46. Wright P., Birkett M., David S.R., et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 158 (2001) 1149-1151
47. Meehan K.M., Wang H., David S.R., et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 26 (2002) 494-504
48. Meehan K., Zhang F., David S., et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 21 (2001) 389-397
49. Olanzapine for injection: new formulation. No advantage in agitated patients. Prescrire Int 13 (2004) 92-93
50. Breier A., Meehan K., Birkett M., et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 59 (2002) 441-448
51. Zyprexa Package Insert. Indianapolis, IN: Eli Lilly and Company; 1997, updated September 2004.
52. Tulloch K.J., and Zed P.J. Intramuscular olanzapine in the management of acute agitation. Ann Pharmacother 38 (2004) 2128-2135